12/4/2019 | IGLM | Roche announces pricing, early results of tender offer for six series
|
12/4/2019 | IGLM | Roche announces early results of capped tender offer for six series
|
11/19/2019 | IGLM | Roche to pay up to $2 billion in tenders for six series of notes
|
10/7/2015 | IGLM | Roche holders tender $275,000 more 7% notes, $5.44 million 6% notes
|
9/23/2015 | IGLM | Roche gives early tender update in offer for $1 billion of three notes
|
9/9/2015 | IGLM | Roche begins tender offer for up to $1 billion of three note series
|
12/31/2009 | IG | Outlook 2010: Drug companies, money managers lead 2009's notable deals
|
10/28/2009 | HYPV | New Issue: PDL BioPharma subsidiary to issue $300 million 10.25% notes due 2015
|
10/28/2009 | SS | PDL BioPharma to monetize royalties, pay special dividend in 2009
|
3/27/2009 | IG | Moody's lowers Roche, keeps Genentech on review
|
3/26/2009 | SS | Roche completes tender offer for Genentech
|
3/17/2009 | IG | Market Commentary: Pfizer sells $13.5 billion bond issue; State Street, SoCal Edison price; Pfizer bonds tighten
|
3/13/2009 | SS | Market Commentary: Market unsure of CV Therapeutics bidding war; Roche to close on Genentech before month's end
|
3/12/2009 | SS | Market Commentary: Genentech OKs latest bid; bidding war on way for CV Therapeutics; CF Industries pushes for Terra deal
|
3/9/2009 | SS | Market Commentary: Merck plows over Schering-Plough; Dow, Rohm & Haas settle; Genentech wants more from Roche
|
3/6/2009 | SS | Market Commentary: Roche ups bid for Genentech; Rohm & Haas investors bank on talks; Whole Foods readies for competition
|
3/6/2009 | SS | Roche increases per-share offer price for Genentech to $93 in effort to close deal
|
3/2/2009 | SS | Market Commentary: NRG buy of Reliant assets may slow down Exelon; IPC takes out Max; traders brace for Dow to hit 6,000
|
2/23/2009 | SS | Genentech rejects Roche's tender offer, urges shareholders to do the same
|
2/10/2009 | SS | Market Commentary: Market frowns on Ticketmaster union; investors want higher Genentech bid; SiRF buyout gives best option
|
2/9/2009 | SS | Market Commentary: Biogen ripe for $76-a-share buyout; Genentech buyout bid opens; Rohm & Haas pressures Dow Chemical
|
2/9/2009 | SS | Roche begins tender offer for Genentech
|
1/30/2009 | SS | Roche plans cash tender offer for Genentech shares; Genentech urges shareholders to hold off
|
1/30/2009 | SS | Market Commentary: Genentech bid lacks support; Wyeth buyout includes hefty breakup fees; Exelon moves for NRG control
|
1/27/2009 | SS | Market Commentary: Roche bid for Genentech predicted to increase; CV not likely to bite at Astellas offer, analyst says
|
1/16/2009 | IG | Moody's: Genentech unaffected
|
1/13/2009 | SS | Market Commentary: Elan moves closer to sale block; second bid for Genentech expected; Puget trades at discount to deal
|
12/18/2008 | SS | Market Commentary: Exelon puts on regulatory show; Huntsman makes gains; Genentech shares move closer to bid price
|
8/22/2008 | SS | Market Commentary: King reveals nixed bid for Alpharma; Genentech will pay to keep staff; Sovereign gyrates on GSE fears
|
8/13/2008 | SS | Genentech says 'no' to Roche's plan to take control
|
8/13/2008 | SS | Market Commentary: eBay bids for Gmarket; Longs jumps on CVS offer; Genetech spurns Roche offer
|
8/4/2008 | SS | Market Commentary: ImClone rejects $60 per share offer; Blackstone shops for theme parks; PeopleSupport jumps on Aegis buy
|
7/25/2008 | SS | Market Commentary: Cleveland-Cliffs moves higher, possibly signaling arbs' expectation of sale
|
7/22/2008 | IG | Moody's may cut Genentech
|
7/21/2008 | SS | Market Commentary: Yahoo!, Icahn settle proxy fight; Roche puts up $43.7 billion for Genentech; private equities try TransAlta
|
7/21/2008 | SS | Roche offers $43.7 billion for full control of Genentech
|
9/7/2007 | IG | Market Commentary: High-volume week sees more than $21.6 billion new issues; pace could continue following stability
|
5/4/2007 | SS | Extended waiting period moves Genentech, Tanox merger close to third quarter
|
4/23/2007 | SS | Market Commentary: MedImmune deal rekindles buzz of biotech buyouts; Genesco gains; Vonage eyed
|
11/16/2006 | BT | Genentech reiterated at buy by Jefferies
|
11/13/2006 | BT | Genentech reiterated at buy by Jefferies
|
11/10/2006 | BT | Market Commentary: Tanox soars 45% on Genentech buy; Targeted Genetics adds 26%, Pozen higher; Insmed, Tercica better
|
11/10/2006 | BT | RBC puts Genentech at outperform
|
11/10/2006 | BT | Genentech kept at buy by Merrill
|
11/10/2006 | BT | Jefferies says buy Genentech
|
11/10/2006 | BT | Genentech at outperform by Bear Stearns
|
11/9/2006 | BT | Genentech keeps buy from Merrill
|
11/9/2006 | BT | RBC puts Genentech at outperform
|
11/8/2006 | BT | Genentech held at buy by Merrill
|
10/12/2006 | BT | Bear Stearns gives Genentech outperform rating
|
10/12/2006 | BT | Merrill keeps Genentech at buy
|
10/12/2006 | BT | Genentech kept at outperform by RBC
|
10/11/2006 | BT | Market Commentary: Genentech slides, Xoma adds 8%; Genzyme eases; NitroMed sinks; Oscient gains; Northfield loses 3%
|
10/11/2006 | BT | Jefferies keeps Genentech at buy
|
10/11/2006 | BT | RBC maintains Genentech at outperform
|
10/11/2006 | BT | Genentech kept at buy by Merrill
|
10/10/2006 | BT | Genentech reports unrestricted cash and investments of $4.0 billion for third quarter
|
10/9/2006 | BT | Genentech at buy by Jefferies
|
10/5/2006 | BT | Genentech at outperform by RBC
|
10/5/2006 | BT | Merrill rates Genentech at buy
|
10/4/2006 | BT | Merrill reiterates Genentech at buy
|
10/3/2006 | BT | Merrill analyst says third-quarter biotech earnings could be mixed
|
10/3/2006 | BT | Market Commentary: Acorda shoots up 32%; Isis lower after analyst day; Gilead off 3.5%, Myogen eases; Amgen better
|
9/28/2006 | BT | Genentech maintained at outperform by RBC
|
9/27/2006 | BT | Genentech rated at buy by Jefferies
|
9/22/2006 | BT | Market Commentary: Amgen leads sector lower; Dyax gains on Kos' loss; Oscient rises; Gene Logic up; Discovery Labs off
|
9/19/2006 | BT | S&P boosts Genentech
|
9/18/2006 | BT | Market Commentary: Genentech steady on Glaxo filing; Cell Therapeutics, Inovio gain on deals; MannKind up, Nektar down
|
9/14/2006 | BT | Merrill has Genentech at buy
|
9/14/2006 | BT | Market Commentary: Threshold, Discovery Labs gain on widespread deal speculation; Curis better; Genzyme gains 3%
|
9/11/2006 | BT | Merrill maintains Genentech at buy
|
9/11/2006 | BT | Genentech reiterated at buy by Jefferies
|
9/11/2006 | BT | Market Commentary: Genentech falls on Avastin delay; Vertex pitches $300 million deal; OSI off 2%; Genitope loses 5%
|
9/11/2006 | BT | Genentech at RBC by outperform
|
9/1/2006 | BT | Curis, Genentech stop co-development of basal cell carcinoma drug
|
9/1/2006 | BT | Market Commentary: Sanofi flu news pushes smaller biotechs lower; BioDelivery off 10%; Curis slips on R&D shift
|
8/28/2006 | BT | Genentech and Biogen say phase 2 study of Rituxan for MS met primary endpoint
|
8/28/2006 | BT | Genentech keeps buy rating from Merrill
|
8/28/2006 | BT | Market Commentary: Discovery Partners up 9% on MedImmune, Infinity pact; EPIX plunges; Sinovac soars; PDL up
|
8/18/2006 | BT | Genentech reiterated at outperform by Bear
|
8/14/2006 | BT | Merrill keeps Genentech at buy
|
8/11/2006 | BT | Genentech updates sBLA application for Herceptin in breast cancer at FDA's request
|
7/25/2006 | BT | Market Commentary: Encysive plunges 40%; Momenta gains 38%; Nastech rises; Enzon up; Connetics firms
|
7/25/2006 | BTCV | New Issue: Morgan Stanley prices $12 million 8% Sparqs exchangeable for Genentech
|
7/25/2006 | BT | Genentech, Inotek to collaborate on cancer treatment based on poly polymerase inhibitors
|
7/12/2006 | BT | Jefferies reiterates Genentech at buy
|
7/12/2006 | BT | RBC reiterates Genentech at outperform
|
7/12/2006 | BT | Genentech at buy by Merrill
|
7/12/2006 | BT | Market Commentary: Genzyme, Genentech 2Q results counteract; Curis retraces losses; Antigenics, CV, Cell Genesys up
|
7/11/2006 | BT | Curis, Genentech to halt phase 1 basal cell carcinoma trial
|
7/11/2006 | BT | Genentech second-quarter sales up 42%, enrollment begins in five separate trials
|
7/11/2006 | BT | Genentech given a buy rating by Jefferies
|
7/10/2006 | BT | Merrill expects strong EPS for Genentech
|
7/5/2006 | BT | Genentech reiterated at buy by Merrill
|
7/5/2006 | BT | Market Commentary: DOV seesaws on CEO exit, closes higher; Neurocrine slides further; Insmed drops 8%; Tercica off 1%
|
7/3/2006 | BT | Jefferies rates Genentech at buy
|
7/3/2006 | BT | Market Commentary: Encore cheered as it goes private on Blackstone buyout at a 36% premium; Siemens, Bayer up
|
6/30/2006 | BT | Genentech's Lucentis receives FDA approval for treatment of wet AMD
|
6/30/2006 | BT | Genentech reiterated at outperform by RBC
|
6/27/2006 | BT | Merrill keeps Genentech at buy
|
6/27/2006 | BT | Genentech stops phase 3 trial of Avastin after failure to meet endpoint of survival
|
6/27/2006 | BT | Genentech reiterated at outperform by RBC
|
6/26/2006 | CV | Morgan Stanley to sell 8% Sparqs exchangeable for Genentech
|
6/22/2006 | BT | Genentech, Biogen say Rituxan reduces joint erosion, damage in arthritis patients
|
6/21/2006 | BT | Merrill keeps Genentech at buy
|
6/21/2006 | BT | FDA approves Avastin with chemotherapy to treat second-line metastatic colorectal cancer patients
|
6/21/2006 | BT | Jefferies reiterates Genentech at buy
|
6/12/2006 | BT | Merrill upgrades Genentech to buy
|
6/5/2006 | BT | Jefferies maintains Genentech at buy
|
6/5/2006 | BT | Genentech at outperform rating from RBC
|
6/5/2006 | BT | Genentech, OSI report Avastin plus Tarceva limits progression in non-small cell lung cancer
|
6/5/2006 | BT | Genentech maintained at neutral by Merrill
|
6/2/2006 | BT | Genentech: 12-month data shows Lucentis prevents age-related blindness
|
6/2/2006 | BT | Merrill Lynch maintains buy on Genentech
|
5/25/2006 | BT | Genentech files license application to use Avastin in breast cancer
|
5/25/2006 | BT | Market Commentary: Cubist explodes ahead of Cubicin vote; Encysive advances; Seattle Genetics, Progenics gain on pact
|
5/23/2006 | BT | Roche, Genentech: Recruitment to resume in Avastin phase 3 trial in early stage colon cancer
|
5/19/2006 | BT | Genentech at outperform by RBC
|
5/9/2006 | BT | Genentech to fund Curis researchers in Hedgehog carcinoma study
|
4/21/2006 | BT | Genentech extends stock repurchase program to June 2007, total to $6 billion
|
4/21/2006 | BT | Market Commentary: Omrix settles above water but on deep-discount pricing; Affymetrix plunges 14%; Genitope gains 3%
|
4/12/2006 | BT | Bear Stearns maintains Genentech at outperform
|
4/12/2006 | BT | Genentech at buy by Jefferies
|
4/11/2006 | BT | Genentech files biologics application for Avastin with chemotherapy in lung cancer
|
4/11/2006 | BT | Genentech says revenue nearly hits $2 billion in first quarter, EPS up 44% to $0.39
|
4/10/2006 | BT | Genentech at buy rating from Jefferies
|
4/7/2006 | BT | Jefferies puts Genentech at buy
|
4/3/2006 | BT | Genentech maintained at neutral by Merrill
|
3/30/2006 | BT | Genentech, Biogen submit sBLA for Rituxan in non-Hodgkin's lymphoma
|
3/24/2006 | BT | Genentech licenses BioWa Potelligent technology for use in antibody development
|
3/20/2006 | BT | Jefferies puts Genentech at buy
|
3/20/2006 | BT | Merrill keeps Genentech at neutral
|
3/17/2006 | BT | Genentech provides investors with strategic plan overview, company updates
|
3/16/2006 | BT | Merrill keeps Genentech at neutral
|
3/2/2006 | BT | Genentech at neutral by Merrill
|
3/2/2006 | BT | Market Commentary: Genentech recoups from Avastin blow; ImClone slumps; Nastech drops; NitroMed strikes new low
|
3/1/2006 | BT | Genentech at neutral by Merrill
|
3/1/2006 | BT | Genentech, Biogen Idec: FDA approves Rituxan for rheumatoid arthritis
|
3/1/2006 | BT | Jefferies gives Genentech buy rating
|
2/28/2006 | BT | FDA grants Genentech priority review for Lucentis for macular degeneration
|
2/17/2006 | BT | Jefferies rates Genentech at buy
|
2/15/2006 | BT | Genentech seeks FDA OK for use of Herceptin in early stage HER2-positive breast cancer
|
2/13/2006 | BT | Genentech: Recruitment suspended in Avastin phase 3 cancer trial amid safety concerns
|
2/13/2006 | BT | Merrill maintains Genentech at neutral
|
2/13/2006 | BT | Jefferies rates Genentech at buy
|
2/13/2006 | BT | Market Commentary: Amgen up after-hours as $4 billion convert emerges; Genentech off; Adolor down on deal; Alnylam up
|
2/10/2006 | BT | Genentech, Biogen receive FDA OK for Rituxan Plus CHOP for non-Hodgkin's lymphoma
|
2/8/2006 | BTCV | New Issue: Barclays sells $1.5 million 11.85% exchangeables linked to Genentech
|
2/6/2006 | BTCV | Barclays plans issue of 11.85% exchangeables linked to Genentech
|
1/31/2006 | BTCV | New Issue: Citigroup prices $31.5 million notes exchangeable for Genentech at 0.5%, up 19.2%
|
1/30/2006 | BT | Jefferies gives Genentech buy rating
|
1/26/2006 | BT | Market Commentary: Altus rockets out of gate; Teva talk tightened; Alexion zooms; Amylin better; Cephalon gains; Nektar rises
|
1/26/2006 | BT | Amgen, Genentech sign license agreements for antibody patents
|
1/25/2006 | BT | Market Commentary: Teva launches $2.75 billion bonds; NitroMed pockets $52.6 million; SGX Pharma sweetens IPO talk
|
1/24/2006 | BT | Jefferies gives Genentech buy rating
|
1/17/2006 | BT | Genentech's phase 3 data shows Lucentis improved vision in patients with macular degeneration
|
1/17/2006 | BT | Genentech maintained by Merrill at neutral
|
1/17/2006 | BT | Jefferies maintains buy for Genentech
|
1/13/2006 | BT | Market Commentary: Nektar up over 10% on Pfizer's move; Encysive, Alexion up big; Biopure loses 4% after follow-on
|
1/12/2006 | BT | Market Commentary: OSI punishment over Eyetech buy continues; NPS up; PDL plunges; Genta; Favrille, Illumina all higher
|
1/12/2006 | CV | Market Commentary: Convertibles market turns mostly lower; biotechs, autos, oil services down, but Six Flags gains
|
1/11/2006 | BT | Genentech maintained by Bear Stearns at outperform
|
1/11/2006 | BT | Jefferies reiterates Genentech at buy
|
1/11/2006 | BT | Market Commentary: PDL, OSI Pharma, Biogen dive; Altus IPO launches, Vertex eases; Novogen shelves Glycotex IPO
|
1/11/2006 | BT | Merrill downgrades Genentech to neutral
|
1/9/2006 | BT | Genentech maintained by Jefferies at buy
|
1/6/2006 | BT | Genentech, Perlegen collaborate to study genetics of cancer
|
1/6/2006 | BT | Market Commentary: Affymetrix lower, Millennium up on guidance; amid rotation into small caps Amgen, Genentech slide
|
12/30/2005 | BT | Genentech files application for Lucentis to treat neovascular wet age-related macular degeneration
|
12/30/2005 | BT | Genentech maintained by Jefferies at buy
|
12/30/2005 | BT | Merrill maintains Genentech at buy
|
12/30/2005 | BT | Genentech still buy, Jefferies says
|
12/19/2005 | BT | Genentech submits sBLA for Avastin to treat colorectal cancer
|
12/13/2005 | BT | Genentech signs up for fourth TAP license with ImmunoGen
|
12/5/2005 | BT | OxiGENE starts trial that pairs CA4P vascular-disrupting compound with Genentech's Avastin
|
12/1/2005 | BT | Market Commentary: Rigel Pharma tromped; Oxigene, Biopure launch follow-on deals; Lexicon, LabCorp, Quigley higher
|
12/1/2005 | BT | Lexicon, Genentech expand alliance to develop new drugs using Lexicon's gene knockout technology
|
12/1/2005 | BT | Lexicon, Genentech expand alliance to develop new drugs using Lexicon's gene knockout technology
|
11/28/2005 | BT | Market Commentary: Merck pressures biotech sector; Amgen, Genentech lead slide; Enzon, BioCryst, Pozen up a tad
|
11/14/2005 | BT | Market Commentary: OSI, Eyetech tie knot; Genentech hits new high; SkyePharma soars on buyout interest; Onyx launches
|
11/8/2005 | BT | William Blair reinitiates Genentech coverage at market perform
|
11/8/2005 | BT | Merrill Lynch reiterates Genentech at buy
|
11/2/2005 | BT | OSI, Genentech get FDA approval for Tarceva to treat pancreatic cancer
|
10/31/2005 | BT | Biogen Idec, Genentech receive FDA priority review for Rituxan treatment of rheumatoid arthritis
|
10/20/2005 | BT | Genentech collaborates with nonprofit to advance brain cancer treatment
|
10/18/2005 | BT | Genentech maintained by Merrill Lynch at buy
|
10/18/2005 | BT | Genentech drops Avastin/Tarceva study in kidney cancer
|
10/17/2005 | BT | Amgen, Genentech, Celgene among Merrill's picks for a rally, report says
|
10/13/2005 | BT | Array BioPharma, Genentech expand oncology collaboration
|
10/13/2005 | BT | Curis receives second extension of funding from Genentech
|
10/11/2005 | BT | Market Commentary: OSI Pharma off as Genentech reports Tarceva weakness; ImClone up at Abgenix expense
|
10/7/2005 | BT | Jefferies raises Genentech earnings forecast
|
9/28/2005 | BT | Market Commentary: Panacos, SkyePharma add to deal slate; Incyte, Endo drop on news; Electro-Optic rejigs talk, syndicate
|
9/27/2005 | BT | Genentech reiterated by Merrill at buy
|
9/27/2005 | BT | Market Commentary: Sunesis sinks after below-range IPO; Biogen, Elan bounce then retreat; Genentech sharply lower
|
9/26/2005 | BT | Genentech maintained by Jefferies at buy
|
9/26/2005 | BT | Genentech maintained by Merrill Lynch at buy
|
9/26/2005 | BT | Market Commentary: Eye drug names viewed in mixed fashion; Ligand gains on hopes of sale; Endo plunges on secondary
|
9/21/2005 | BT | Genentech price target raised by Merrill Lynch
|
9/14/2005 | BT | Genentech kept by Bear Stearns at outperform
|
9/14/2005 | BT | Genentech maintained by Jefferies at buy
|
9/12/2005 | BT | Geron joins Myogen for Thursday; Cell Genesys up on back of Geron; OSI Pharma plummets on Tarceva
|
9/8/2005 | BT | Genentech maintained by Jefferies at buy
|
9/8/2005 | BT | Genentech reiterated by Merrill Lynch at buy
|
9/8/2005 | BT | Genentech reiterated by Bear at outperform
|
9/7/2005 | BT | Mature U.S. biotechs have stronger credit than industrials but weaker than Big Pharma, S&P says
|
8/1/2005 | BT | Market Commentary: Anadys, Ariad, Nastech offerings join ZymoGenetics for this week; Amgen, Abgenix up on fast track
|
7/27/2005 | BTCV | New Issue: Morgan Stanley prices $18 million 7% Sparqs exchangeable for Genentech
|
7/20/2005 | BT | Market Commentary: Accentia, Adams IPOs on deck as biotech index surges; BioMarin, Keryx bode well; Amgen rockets
|
7/19/2005 | BT | Genentech maintained by Merrill at buy
|
7/19/2005 | BT | Market Commentary: Able bankruptcy sparks buying by restructuring specialists; Amgen a blowout; Genentech weighs on QLT
|
7/18/2005 | BT | Market Commentary: Momenta off on secondary sale; Geron zooms on Merck pact; ViroPharma up; Amgen quiet
|
7/15/2005 | BT | Market Commentary: Accentia IPO pushed back; Keryx zooms; Rigel off; Adherex gets big partner; Abgenix seen in play
|
7/14/2005 | BT | Market Commentary: Genentech active; CryoCor IPO trades up, sinks; Mylan prices tight, center; BioMarin off on follow-on
|
7/13/2005 | BT | Market Commentary: Genentech floats $2 billion in bonds; Advanced Medical Optics convert dished up; Mylan talk out
|
7/13/2005 | BT | New Issue: Genentech sells $2 billion bonds; 5-year at 45 bps, 10-year at 60 bps, 30-year at 87 bps
|
7/13/2005 | BT | S&P rates Genentech notes A+
|
7/13/2005 | BT | Moody's gives Genentech notes A1
|
7/13/2005 | BT | Genentech target raised by Jefferies
|
7/12/2005 | BT | Market Commentary: Planet Biotech targets VC funds; Rigel, Keryx decline; Genentech rises, pushes OSI Pharma higher
|
7/12/2005 | BT | Genentech target raised by Merrill
|
7/12/2005 | BT | Genentech target raised by Baird
|
7/11/2005 | BT | Merrill biotech analysts see interest in sector ahead of second quarter earnings
|
7/11/2005 | BT | Market Commentary: Accentia runs into resistance; Canadian biotechs tap PIPEs; eyes on Genentech; Mylan up
|
7/6/2005 | BT | Market Commentary: Adams Respiratory sets IPO price; Accentia, Advanced Life Sciences seen on deck; Amgen issues higher
|
6/24/2005 | BT | Market Commentary: HemoSense IPO delayed yet again; Cephalon off, Alkermes up on pact for alcoholism shot; Genentech up
|
6/21/2005 | BT | Market Commentary: Critical Therapeutics zooms after financing round; Mylan launches bank facility; Eyetech seen higher
|
8/26/2004 | CV | New Issue: Citigroup prices $18 million 7.5% Elks exchangeable for Genentech
|
6/23/2004 | CV | New Issue: ABN Amro sells $1.85 million 9% reverse exchangeables linked to Genentech
|
4/26/2004 | CV | Market Commentary: OSI Pharma skyrockets amid buying frenzy as stock shoots up 139%; 4 new deals emerge
|
3/3/2004 | CV | Market Commentary: Disney little changed on concerns besides Eisner; PSS soars to 106; Toys up on hoped-for store sales
|
8/26/2003 | CV | Market Commentary: Mixed bag, as convertibles track stocks in another slow session; Xerox issue soars on dividend
|
6/26/2003 | CV | Roche 0% convert due 2021 offers cheap volatility: Deutsche analysts
|
9/10/2002 | CV | Market Commentary: Market stalls on terrorist alert in advance of attack anniversary
|
8/19/2002 | CV | Market Commentary: OSI, ImClone wounded; retailers build on strong surge at Lowe's
|
5/14/2002 | CV | Market Commentary: Broadbased gains as better retail sales confirm recovery signs
|
4/5/2002 | CV | Market Commentary: Adelphia gains on hiring advisors; Getty Images soars on EPS revision; Genentech falls
|